All Supplementary Data from Recurrent Patterns of Protein Expression Signatures in Pediatric Acute Lymphoblastic Leukemia: Recognition and Therapeutic Guidance

Abstract

<p>This file contains all supplementary tables and figures. Supplemental Table S1. COG treatment protocols pediatric ALL patients. Supplementary Table S2. This table contains the "Rosetta Stone" for the antibody and protein nomenclature (HUGO, MiMI, GeneCards) together with the RPPA staining details. Supplementary Table S3. Protein membership for the 31 defined protein functional groups. Supplementary Table S4. ALL protein constellation membership for the 114 protein clusters. Supplementary Table S5. T-ALL protein constellation membership for the 114 protein clusters. Supplementary Table S6. B-ALL protein constellation membership for the 114 protein clusters. Supplementary Table S7. This table shows the univariate and multivariate Cox Proportional Hazard Model Supplementary Table S8. Protein cluster membership for the leukemic cell lines. Supplementary Fig. S1. Computational work flow. Supplementary Fig. S2. The co-occurrence probability matrices are shown for the PFG ''FLI1'' and ''Apoptosis Occurring''. Supplementary Fig. S3. Principal component analysis for the year of collection and for the processing time of the leukemic samples. Supplementary Fig. S4. (A) Unsupervised hierarchical clustering and (B) principal component analysis plot for the CD34+ cells (black) and the pediatric ALL patient samples (red). Supplementary Fig. S5. Unsupervised hierarchical clustering and k-means for all proteins and ALL patients. Supplementary Fig. S6. Optimization calculation meta-galaxy pediatric ALL. Supplementary Fig. S7. Meta-galaxy analysis restricted to B-ALL cases. Supplementary Fig. S8. Significantly changed protein targets identified for each signature and each constellation. Supplementary Fig. S9. A minimal set of 30 antibodies that could predict classification of patients into signatures. Supplementary Fig. S10. (A) Unsupervised hierarchical clustering of pediatric ALL patient samples and leukemic cell lines (N=95)</p>